June 27, 2024 – Importance of FACIT and other seed stage venture groups in building the local innovation ecosystem. Life sciences commercialization in Canada has a seed venture financing gap where companies fail to establish local roots and intellectual property gravitates to the US, reinforcing the export of jobs and industry experience.
Tag: investment
Newsweek: The New Era of Life Sciences 2024
May 15, 2024 – FACIT President discusses early-stage investing in Canada in an interview with Newsweek’s Investment Reports and appeared in The New Era of Life Sciences 2024. FACIT is an innovative organization focused on bridging the gap between cancer research breakthroughs and their commercialization, thereby accelerating the journey of scientific discoveries from the laboratory to the marketplace.
FACIT-seeded Fusion Pharmaceuticals acquired for up to US$2.4B by AstraZeneca
March 20, 2024 – FACIT’s portfolio company Fusion Pharmaceuticals is being acquired by AstraZeneca for a total transaction value of up to $2.4 billion. Congratulations to the team at Fusion for building value over the last decade that will have a lasting impact on patients with cancer and the Ontario economy.
Read More from FACIT-seeded Fusion Pharmaceuticals acquired for up to US$2.4B by AstraZeneca
FACIT portfolio company Tenomix secures an all-Canadian investment round for colorectal cancer diagnostic
March 1, 2024 – FACIT congratulates London, Ontario based Tenomix Inc. (“Tenomix”) on successfully reaching a key milestone in closing its latest financing round to help propel the medtech start-up. Tenomix’s bench-top device will save time and costs by automating the process of lymph node identification in resected tissue while providing more accurate cancer staging for better patient care.
FACIT generates $1.5 billion in follow-on investment
March 29, 2023 – FACIT announced $1.5 billion in follow-on investment attracted to its portfolio of cancer biotechnology start-ups in Ontario, a significant milestone for life science commercialization in Canada.
Read More from FACIT generates $1.5 billion in follow-on investment
CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer
March 23, 2023 – CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.
FACIT’s Prospects Fund invests in two emerging Ontario diagnostics for colorectal and prostate cancers
September 16, 2021 – September 16, 2021 – Both innovations were previous finalists in FACIT’s 2021 Falcons’ Fortunes pitch competition.
FACIT leads seed round in Nanology Labs
May 18, 2021 – May 18, 2021 – FACIT deploys Ontario First capital, enables rising local start-up to reach critical value inflection point. FACIT has previously supported Nanology, spun out of the University of Toronto, through both its early-stage Prospects Oncology Fund and seed-stage Compass Rose Oncology Fund.
FACIT crowns 2021 winner of Falcons’ Fortunes pitch competition; announces follow-on investment in 2020 winner, Bridge7 Oncology
February 4, 2021 – February 4, 2021 – FACIT’s Prospects Oncology Fund and its annual pitch competition help to advance Ontario oncology innovations.
FACIT fuels promising made-in-Ontario breast cancer therapeutic and medtech innovations through Prospects Oncology Fund
December 10, 2020 – December 10, 2020 – The newest recipients of Ontario First seed capital include Dr. Rebecca Laposa of the University of Toronto, as well as London-based start-up Multi-Magnetics Inc.